Early Detection of Ovarian Cancer: Promise and Reality

  • Robert C. BastJr.
  • Nicole Urban
  • Viji Shridhar
  • David Smith
  • Zhen Zhang
  • Steven Skates
  • Karen Lu
  • Jinsong Liu
  • David Fishman
  • Gordon Mills
Part of the Cancer Treatment and Research book series (CTAR, volume 107)


One of the most promising approaches to the control of many epithelial malignancies is to detect cancers before they have metastasized. Effective screening strategies have been developed and are widely utilized in clinical practice to detect cervical, breast, prostate and colorectal cancers. In the case of epithelial ovarian cancer, the ability to cure early stage disease provides an attractive rationale for the development of similarly effective screening strategies. Despite the improvement in median survival achieved with contemporary cytoreductive surgery and combination chemotherapy, ovarian cancer that has spread beyond the pelvis at the time of diagnosis can be cured in no more than 20% of cases. By contrast, when ovarian cancer is detected in Stage I, before it has spread from the ovaries, 90% of women can be cured with currently available therapy. At present, however, only 25% of ovarian cancers are diagnosed in Stage I (Ries et. al, 1999). Consequently, detection of preclinical disease at an earlier stage in a larger fraction of women might improve overall survival.


Ovarian Cancer Ovarian Carcinoma Epithelial Ovarian Cancer Ovarian Cancer Patient Tissue Polypeptide Antigen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ala-Fossi SL, Maenpaa J, Blauer M, Tuohimaa P, Punnonen R. (2000). Inhibin A, B and pro-alpha C in serum and peritoneal fluid in postmenopausal patients with ovarian tumors, Eur J Endocrinol 142, 334–9.Google Scholar
  2. Ardekani AM, Hitt B, Brown MR, Fishman DA, Mills G, Liotta L, Petricoin EF, Kohn EC. (2001). A high throughput proteomic approach to serum marker development for discrimination between ovarian cancer patients and unaffected individuals, Proc Soc Gynecol Oncol 32: 102.Google Scholar
  3. Avail Lundqvist E, Nordstrom L, Sjovall K, Eneroth P. (1989). Evaluation of seven different tumour markers for the establishment of tumour marker panels in gynecologic malignancies, Eur J Gynaecol Oncol 10, 395–405.Google Scholar
  4. Baron AT, Lafky JM, Boardman CH, Balasubramaniam S, Suman VJ, Podratz KC, Maihle NJ. (1999). Serum sErb B1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer, Can Epid Bio Prey 8, 129–37.Google Scholar
  5. Baron AT, Lafky JM, Boardman CH, Balasubramaniam S, Suman VJ, Podratz KC, Maihle NJ. (1999). Serum sErbBl and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer, Cancer Epidemiol Biomarkers 8, 129–37.Google Scholar
  6. Barton DP, Blanchard DK, Michelini-Norris B, Nicosia SV, Cavanagh D, Djeu JY. (1993). High serum and ascitic soluble interleukin-2 receptor alpha levels in advanced epithelial ovarian cancer, Blood 81, 424–9.PubMedGoogle Scholar
  7. Barrenetxea G, Martin-Mateos M, Barzazan Mj, Montoya F, Matia JC, Rodriquez-Escudero FJ. (1990). Serum CA 125, CA 15.3 and CA 19.9 levels and surgical findings in patients undergoing second look operations for ovarian carcinomas, Eur J Gynaecol Oncol,i 1, 36974.Google Scholar
  8. Bast RC Jr, Klug TL, St. John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR Jr, Knapp RC. (1983). A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer, New Engl J Med 309,883–887.Google Scholar
  9. Bast RC jr, Knauf S, Epenetos A, Khokia B, Daly L, Tanner M, Soper J, Creasman W, Gall S, Knapp RC. (1991). Coordinate elevation of serum markers in ovarian cancer but not in benign disease, Cancer 68, 1758–63.CrossRefGoogle Scholar
  10. Bast RC Jr, Siegal FP, Runowicz C, Klug TL, Zurawski VR Jr, Schonholz D, Cohen CJ, Knapp RC. (1985). Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma, Gynecol Oncol 22, 115–120.PubMedCrossRefGoogle Scholar
  11. Bell R, Petticrew M, Sheldon T. (1998). The performance of screening tests for ovarian cancer: results of a systematic review, Br J Obstet Gynaec 105, 1136–47.CrossRefGoogle Scholar
  12. Ben-Arie A, Hagay Z, Ben-Hur H, Open M, Dgani R. (1999). Elevated serum alkaline phosphatase may enable early diagnosis of ovarian cancer, Eur J Obstet Gynecol Reprod Biol 86, 69–71.PubMedCrossRefGoogle Scholar
  13. Beneditti Panici P, Scambia G, Baiocchi G, lacobelli S, Mancuso S. (1989). Predictive value of multiple tumor marker assays in second-look procedures for ovarian cancer, Gynecol Oncol 35, 386–9.CrossRefGoogle Scholar
  14. Berek JS, Bast RC Jr. (1995). Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection, Cancer 76, 2092–6.Google Scholar
  15. Berek JS, Chung C, Kaldi K, Watson JM, Knox RM, Martinez-Maza O. (1991). Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer, Am J Obstet Gynecol 164, 1038–42.PubMedGoogle Scholar
  16. Blaakaer J, Hogdall CK, Micic S, Toftager-Larsen K, Hording U, Bennett P, Bock J. (1995). Ovarian carcinoma serum markers and ovarian steroid activity—is there a link in ovarian cancer? A correlation of inhibin, tetranectin and CAl25 to ovarian activity and the gonadotropin levies, Eur J Obstet Gynecol Reprod Biol 59, 53–6.PubMedCrossRefGoogle Scholar
  17. Boardman CH, Baron AT, Lafky JM, Metzinger D, Sunman VJ, Fishman DA, Podratz KC, Maihle NJ. (2000). Soluble ERBB/EGFR as a tumor biomarker in women with epithelial ovarian cancer, Proceedings American Association for Cancer Research, 41, Abstract #4635, 730.Google Scholar
  18. Bon GG, Verheijen RH, Zuetenhorst JM, van Kamp GJ, Verstraeten AA, Kenemans P. (1996). Mucin-like carcinoma-associated antigen serum levels in patients with adenocarcinomas originating from ovary, breast and colon, Gynecol Obstet Invest 42, 58–62.PubMedCrossRefGoogle Scholar
  19. Bourne TH, Campbell S, Reynolds KM, Whitehead MI, Hampson J, Royston P, Crayford TJB, Collins WP. (1993). Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging, Br Med J 306, 1025–9.CrossRefGoogle Scholar
  20. Boume TH, Campbell S, Reynolds KM, Whitehead MI, Hampson J, Royston P, Crayford T, Collins WP. (1993). Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging, Br Med J 306, 1025–9.CrossRefGoogle Scholar
  21. Campbell S, Ghan V, Royston P, Whitehead M, Collins W. (1989). Transabdominal ultrasound screening for early ovarian cancer, Br Med J 299, 1363–7.CrossRefGoogle Scholar
  22. Cane P, Azen C, Lopez E, Platt LD, Karlan BY. (1995). Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening, Gynecol Oncol 57, 240–5.PubMedCrossRefGoogle Scholar
  23. Castelli M, Battaglia F, Scambia G, Panici PB, Ferrandina G, Mileo AM, Mancuso SGoogle Scholar
  24. Ferrini U. (1991). Immunosuppressive acidic protein and CA 125 levels in patients with ovarian cancer, Oncology 48, 13–7.PubMedCrossRefGoogle Scholar
  25. Castelli M, Romano P, Atlante G, Pozzi M, Ferrini U. (1987). Immunosuppressive acidic protein and CA 125 levels in patients with ovarian cancer, Oncology 48, 13–7.CrossRefGoogle Scholar
  26. Cohen LS, Escobar PF, Scharm C, Glimco B, Fishman DA. Three-dimensional power doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction, submitted for publication.Google Scholar
  27. Collins WP, Boume TH, Campbell S. (1998). Screening strategies for ovarian cancer, Curr Opin Obstet Gynecol, 10, 33–9.PubMedCrossRefGoogle Scholar
  28. Consensus Development Panel on ovarian cancer. (1995). JAMA 273, 491–7.CrossRefGoogle Scholar
  29. Crump C, McIntosh MW, Urban N, Anderson G, Karlan BY. (2000). Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening, Cancer Epidemiol Biomarkers Prevent, 9, 1107–11.Google Scholar
  30. De Brujin HW, ten Hoor KA, Boonstra H, Marink J, Krans M, Aalders JG. (1993). Cancer-associated antigen CA 195 in patients with mucinous ovarian tumours: a comparative analysis with CEA, TATI, and CA 125 in serum specimens and cyst fluids, Tumour Biol 14, 105–15.CrossRefGoogle Scholar
  31. De Brujn HW, ten Hoor KA, van der Zee AG. (1998). Serum and cystic fluid levels of soluble interleukin-2 receptor-alpha in patients with epithelial ovarian tumors are correlated, Tumour Biol 19, 160–6.CrossRefGoogle Scholar
  32. De Broe ME, Pollet DE. (1988). Multicenter evaluation of human placental alkaline phosphatase as a possible tumor-associated antigen in serum, Clin Chem 34, 1995–9.PubMedGoogle Scholar
  33. Devine PL, McGuckin MA, Quin RJ, Ward BG. (1994). Serum markers CASA and CA 15–3 in ovarian cancer: all MUC1 assays are not the same, Tumour Biol 15, 337–44.PubMedCrossRefGoogle Scholar
  34. Diamandis EP. (2001). Two new ovarian cancer biomarkers, Tumor Markers: A New Era, Santa Barbara, CA.Google Scholar
  35. Diamandis EP, Yousef GM, Soosaipillai AR, Bunting P. (2000). Human kallikrein 6 (zyme/portease M/neurosin): a new serum biomarker of ovarian carcinoma 33, 579–83.Google Scholar
  36. Drescher C, Holt SK, Andersen MR, Anderson G, Urban N. (2000). Reported ovarian cancer screening among a population-based sample in Washington State, Obstet Gynecol 96, 70–4.PubMedCrossRefGoogle Scholar
  37. Eerdekens MW, Nouwen EJ, Pollet DE, Briers TW, De Broe ME. (1985). Placental alkaline phosphatase and cancer antigen 125 in sera of patients with benign and malignant diseases, Clin Chem 31, 687–90.PubMedGoogle Scholar
  38. Einhorn N, Knapp RC, Bast RC, Zurawski VR Jr. (1989). CA 125 assay used in conjunction with CA 15.3 and TAG-72 assays for discrimination between malignant and non-malignant diseases of the ovary, Acta Oncol 28, 655–7.PubMedCrossRefGoogle Scholar
  39. Einhorn N, Sjovall K, Knapp RC, Hall P, Scull RE, Bast RC, Zurawski VR. (1992). Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer, Obstet Gynecol 80, 14–8.PubMedGoogle Scholar
  40. Engelen MJ, de Bruijn HW, Hollema H, ten Hoor KA, Willemse PH, Aalders JG, van der Zee AG. (2000). Serum CA 125, carcinoembryonic antigen, and CA 19–9 as tumor markers in borderline ovarian cancer, Gynecol Oncol 78, 16–20.PubMedCrossRefGoogle Scholar
  41. Fang X, Gaudette D, Fumi T, Mao M, Estrella V, Eder A, Pustilnik T, Sasagwa T, Lapushin R, Yu S, Jaffe RB, Wiener JR, Erickson JR, Mills GB. (2000). Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer, Ann NY Acad Sci 905, 188–208.PubMedCrossRefGoogle Scholar
  42. Fayed ST, Ahmad SM, Kassim SK, Khalifa A. (1998). The value of CA 125 and CA 72–4 in management of patients with epithelial ovarian cancer, Dis Markers 14, 155–60.PubMedGoogle Scholar
  43. Ferdeghini M, Gadducci A, Prontera C, Malagnino G, Fanucchi A, Annicchiarico C, Facchini V, Bianchi R. (1993). Serum soluble interleukin-2 receptor assay in epithelial ovarian cancer, Tumour Biol 14, 303–9.PubMedCrossRefGoogle Scholar
  44. Fishman DA, Cohen LS. (2000). Is transvaginal ultrasound effective for screening asymptomatic women for the detection of early-stage epithelial ovarian carcinoma, Gynecol Oncol 77, 347–49.PubMedCrossRefGoogle Scholar
  45. Gadducci A, Ferdeghini M, Ceccarini T, Prontera C, Faccini V, Bianchi R, Fioretti P. (1989). The serum concentrations of TAG-72 antigen measured with CA 72–4 IRMA in patients with ovarian carcinoma, J Nucl Med Allied Sci 33, 32–6.PubMedGoogle Scholar
  46. Gadducci A, Ferdeghini M, Ceccarini T, Prontera C, Facchini V, Bianchi R, Fioretti P. (1990). A comparative evaluation of the ability of serum CA 125, CA 19–9, CA 15–3, CA 50, CA 72–4 and TATI assays in reflecting the course of disease in patients with ovarian carcinoma, Eur J Gynaecol Oncol 11, 127–33.PubMedGoogle Scholar
  47. Gadducci A, Ferdeghini M, Prontera C, Moretti L, Mariani G, Bianchi R, Fioretti P. (1992). The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis, Gynecol Oncol 44, 147–54.PubMedCrossRefGoogle Scholar
  48. Garzetti GG, Ciavattini A, Lucarini G, Goteri G, RomaniniC, Biagini G. (1996). Increased serum 72 Kda metalloproteinase in serous ovarian tumors: comparison with CA 125, Anticancer Res 16, 2123–7.Google Scholar
  49. Ghazizadeh M, Sasaki Y, Oguro T, Aihara K, Tenjin H, Araki T. (1990). Combined immunohistochemical study of tissue polypeptide antigen and cancer antigen 125 in human ovarian tumours, Histopathology 17, 123–8.PubMedCrossRefGoogle Scholar
  50. Gibson HE, Wong KK, Yiu GK, Muto MM, Berkowitz RS, Cramer DW, Mok SC. Clinical applications of microarray technology: Creatine kinase B is an upregulated gene in epithelial ovarian cancer and shows promise as a serum marker, Society of Gynecologic 32°d Annual Meeting, Abstract 8, 43.Google Scholar
  51. Goldhirsch A, Berger E, Muller O, Maibach R, Misteli S, Buser K, Roesler H, Brunner K. (1988). Ovarian cancer and tumor markers: sialic acid, galactosyltransferase and CA-125, Oncology 45, 281–6.PubMedCrossRefGoogle Scholar
  52. Gonzalez A, Vizoso F, Vazquez J, Ruibal A, Balibrea JL. (1997). Clinical significance of preoperative serum levels of CA 125 and TAG-72 in ovarian cancer, Int J Biol Markers 12, 112–7.PubMedGoogle Scholar
  53. Grosen EA, Granger GA, Gatanaga M, Ininns EK, Hwang C, DiSaia P, Berman M, Manetta A, Emma D, Gatanaga T. (1993). Meausrement of the soluble membrane receptors for tumor mecrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy, Gynecol Oncol 50, 68–77.PubMedCrossRefGoogle Scholar
  54. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. (2001). Cancer statistics, 2001, CA Joum Clin 51, 15–37.CrossRefGoogle Scholar
  55. Guadagni F, Roselli M, Cosimelli M, Ferroni P, Spila A, Cavaliere F, Casaldi V, Wappner G, Abbolito MR, Greiner JW. (1995). CA 72–4 serum marker — a new tool in the management of carcinoma patients, Cancer Invest 13, 227–38.PubMedCrossRefGoogle Scholar
  56. Guerriero S, Ajossa S, Risalvato A, Lai MP, Mais V, Angiolucci, Melis GB. (1998) Diagnosis of adnexal malignancies by using color Doppler energy imaging as a secondary test in persistent masses. Ultrasound Obstet Gynecol 11, 277–82.PubMedCrossRefGoogle Scholar
  57. Halila H, Lehtovirta P, Stenman UH. (1988). Tumour-associated trypsin inhibitor ( TATI) in ovarian cancer, Br J Cancer 57, 304–7.Google Scholar
  58. Hasholzner U, Baumgartner L, Steiber P, Meier W, Hofmann K, Fateh-Moghadam A. (1994). Significance of the tumour markers CA 125 II, CA 72–4, CASA and CYFRA 21–1 in ovarian carcinoma, Anticancer Res 14, 2743–6.PubMedGoogle Scholar
  59. Hasholzner U, Baumgartner L, Steiber P, Meier W, Reiter W, Pahl H, Fateh-Moghadam A. (1996). Clinical significance of the tumour markers CA 125 II and CA 72–4 in ovarian carcinoma, Int J Cancer 69, 329–34.PubMedCrossRefGoogle Scholar
  60. Healy DL, Mamers P, Bangah M, Burger HG. (1993). Clinical and pathophysioloogical aspects of inhibin, Human Reprod, Suppl 2, 138–40.Google Scholar
  61. Hefter L, Mayerhofer K, Nardi A, Reinthaller A, Kainz C, Tempfer C. (2000). Serum soluble Fas levels in ovarian cancer, Obstet Gynecol 96, 65–9.CrossRefGoogle Scholar
  62. Heinonen PK, Kallioniemi OP, Koivula T. (1987). Comparison of CA 125 and placental alkaline phophatase as ovarian tumor markers, Tumori 73, 301–2.PubMedGoogle Scholar
  63. Helzlsouer KJ, Bush TL, Albert AJ, Bass KM, Zacur H, Comstock GW. (1993). Prospective study of serum CA 125 levels as markers of ovarian cancer, JAMA 269, 123–6.Google Scholar
  64. Hogdall CK. (1998). Human tetranectin: methodological and clinical studies, APMIS Suppl 86, 1–31.PubMedGoogle Scholar
  65. Hogdall CK, Hogdall EV, Hordin U, Toftager-Larsen K, Arends J, Norgaard-Pedersen B, CIemmensen I. (1996). Use of tetranectin, CA-125 and CASA to predict residual tumor and survival at second-and third-look operations for ovarian cancer, Acta Oncol 35, 63–9.PubMedCrossRefGoogle Scholar
  66. Hogdall EVS, Hogdall CK, Kjaer SK, Iles R, Xu FJ, Yu, Y, Bast RC Jr, Blaakaer J, Jacobs I. (1999). OVX1 radioimmunoassay results are dependent on the method of sample collection and storage, Clin Chem 45, 692–694.PubMedGoogle Scholar
  67. Hogdall EV, Hogdall CK, Tingulstad S, Hagen B, Nustad K, Xu FJ, Bast RC, Jacobs IJ. (2000). Predictive values of serum tumours markers tetranectin, OVX1, CASA and CAl25 in patients with a pelvic mass, Int J Cancer 89, 519–23.PubMedCrossRefGoogle Scholar
  68. Hording U, Toftager-Larsen K, Dreisler A, Lund B, Daugaard S, Lundvall F, Arends J, Winkel P, Rorth M. (1990). CA 125, placental alkaline phophatase, and tissue polypeptide antigen in the monitoring of ovarian carcinoma. A comparative study of three different tumor markers, Gynecol Obstet Invest 30, 178–83.Google Scholar
  69. Hurteau JA, Woolas RP, Jacobs IJ, Oram DC, Kurman CC, Rubin LA, Nelson DL, Berchuck A, Bast RC Jr, Mills GB. (1995). Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer, Cancer 76, 1615–20.PubMedCrossRefGoogle Scholar
  70. Hurteau JA, Simon HU, Kurman C, Rubin L, Mills GB. (1994). Levels of soluble interleukin-2 receptor-alpha are elevated in serum and ascitic flluid from epithelial ovarian cancer patients, Am J Obstet Geynecol 170, 918–28.Google Scholar
  71. Hutson R, Ramsdale J, Wells M. (1995). p53 protein expression in putative precursor lesions of epithelial ovarian cancer, Histopathology 27, 367–71.Google Scholar
  72. Ind T, Iles R, Shepard J, Chard T. (1997), Serum concentrations of cancer antigen 125, placental alkaline phosphatase, cancer-associated serum antigen and free beta human chorionic gonadotrophin as prognostic markers for epithelial ovarian cancer, Br J Obstet Gynaecol 104, 1024–9.PubMedCrossRefGoogle Scholar
  73. Inoue M, Fujita M, Nakazawa A, Ogawa H, Tanizawa O. (1992). Sialyl-Tn, sialyl-Lewis Xi, CA 19–9, CA 125, carcinoembryonic antigen, and tissue polypeptide antigen in differentiating ovarian cancer from benign tumours, Obstet Gynecol 79, 434–40.PubMedCrossRefGoogle Scholar
  74. Jacobs I, Bast RC Jr. (1989). CAl25 tumour-associated antigen: A review of the literature, Hum Reprod 4, 1–12.Google Scholar
  75. Jacobs IJ, Rivera H, Oram DH, Bast RC Jr. (1993). Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15–3 and TAG 72.3, Br J Obstet Gynaecol 100, 1120–4.PubMedCrossRefGoogle Scholar
  76. Jacobs IJ, Oram DH, Bast RC Jr. (1992). Strategies for improving the specificity of screening for ovarian cancer with tumour-associated antigens CA 125, CA 15–3 and TAG 72.3, Obstet Gynecol 80, 396. 9.Google Scholar
  77. Jacobs I, Stabile I, Bridges J, Kemsley P, Reynolds C, Grudzinskas J, Oram D. (1999). Multimodal approach to screening for ovarian cancer, The Lancet, 268–71.Google Scholar
  78. Jacobs I. (1988). Screening for ovarian cancer by CA 125 measurements. The Lancet, 889Google Scholar
  79. Jacobs IJ, Kohler MF, Wiseman RW, Marks JR, Whitaker R, Kerns BA, Humphrey P, Berchuck A, Ponder BA, Bast RC Jr.. (1992). Clonal origen of epithelial ovarian cancer: Analysis by loss of heterozygosity, p53,mutation and chromosome inactivation, J Natl Cancer Inst 84, 1793–8.PubMedCrossRefGoogle Scholar
  80. Jacobs IJ, Rivera H, Oram DH, Bast RC Jr. Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15–3 and TAG 72.3, Br J Obstet Gynaecol 100, 1120–4.Google Scholar
  81. Jacobs II, Skates S, Davies AP, Woolas RP, Jeyerajah, A, Weidemann P, Sibley K, Oram DH. (1996). Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study, Br Med J 313, 1355–8.CrossRefGoogle Scholar
  82. Kacinski BM, Carter D, Mittal K. (1990). Ovarian adenocarcinomas express fmscomplementary transcripts and fms antigen, often with coexpression of CSF-1, Am J Path 137, 135–47.PubMedGoogle Scholar
  83. Karlan BY, Plkatt LD. (1994). The current status of ultrasound and color doppler imaging in screening for ovarian cancer, Gynecol Oncol 55, S28 - S33.PubMedCrossRefGoogle Scholar
  84. Kenemans P, Verstraeten AA, van Kamp Gj, von Mendsdorff-Pouilly S. (1995). The second generation CA 125 assays, Ann Med 27, 107–13.PubMedCrossRefGoogle Scholar
  85. Kierkegaard O, Mogensen O, Mogensen B, Jakobsen A. (1995). Predictive and prognostic valules of cancer-associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second-look laparotomy for ovarian cancer, Gynecol Oncol 59, 251–4.PubMedCrossRefGoogle Scholar
  86. Knauf S, Bast RC Jr. (1988). Tumor antigen NB/70K and CA 125 levels in the blood of preoperative ovarian cancer patients and controls: a preliminary report of the use of the NB 12123 and CA 125 radioimmunoassays alone and in combination, Int J Biol Markers 3, 75–81.PubMedGoogle Scholar
  87. Koebl H, Schieder K, Neunteufel W, Bieglmayer C. (1989). A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, A 19–9 and CEA in patients with ovarian cancer, Neoplasma 36, 473–8.Google Scholar
  88. Koebl H, Tatra G, Bieglmayer C. (1988). A comparative study of immunosuppressive acidic protein (IAP), CA 125 and acute-phase proteins as parameters for ovarian cancer monitoring, Neoplasma 35, 215–20.PubMedGoogle Scholar
  89. Kohler MF, Kerns BJM, Soper JT, Humphrey PA, Marks JR, Bast RC Jr, Berchuck A. (1993). Mutation and overexpression of p53 in early-stage epithelial ovarian cancer, Obstet Gynecol 81, 643–650.PubMedGoogle Scholar
  90. Kudoh K, Kikuchi Y, Kita T, Tode T, Takano M, Hirata J, Mano Y, Yamamota K, Nagata I. (1999). Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma, Gynecol Obstet Invest 47, 52–7.PubMedCrossRefGoogle Scholar
  91. Kurachi H, Adachi H, Morishige K, Adachi K, Takeda T, Homma H, Yamamota T, Miyake A. (1996). Transforming growth factor-alpha promotes tumor markers secretion from human ovarian cancers in vitro, Cancer 78, 1049–54.PubMedCrossRefGoogle Scholar
  92. Kurjak A, Kupesic S, Breyer B. (1998). The assessment of ovarian tumor angiogensis: What does three-dimensional power Doppler add? Ultrasound Obstet Gynecol 12, 136–146.PubMedCrossRefGoogle Scholar
  93. Kurjak A, Zalud I, Alfirevic Z. (1991). Evaluation of adnexal masses with transvaginal color ultrasound. J Ultrasound Med 10, 295–7.PubMedGoogle Scholar
  94. Lambert-Messerlian GM, Steinhoff M, Zheng W, Canick JA, Gajewski WH, Seifer DB, Schneyer AL. (1997). Multiple immunoreactive inhibin proteins in serum from postmenopausal women with epithelial ovarian cancer, Gynecol Oncol 65, 512–6.PubMedCrossRefGoogle Scholar
  95. Lidor YJ, Xu FJ, Martinez-Maza O, Olt GJ, Marks JR, Berchuck A, Ramakrishnan S, Berek JS, Bast RC Jr. (1993). Constitutive production of macrophage colony stimulating factor and interleukin-6 by human ovarian surface epithelial cells, Exp Cell Res 207, 332–339.PubMedCrossRefGoogle Scholar
  96. Lotzniker M, Pavesi F, Scarabvelli M, Vadacca G, Franchi M, Moratti R. (1991). Tumour associated antigens CA 15.3 and CA 125 in ovarian cancer, Int J Biol Markers 6, 115–21.PubMedGoogle Scholar
  97. Lu KH, Bell DA, Welch WR, Berkowitz RS, Mok SC. (1998). Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors, Cancer Res 58, 2328–30.PubMedGoogle Scholar
  98. Luo L, Bunting P, Scorilas A, Diamandis EP. (2001). Human kallidrein 10: a novel tumor marker for ovarian carcinoma? Clin Chem Acta 306, 111–8.CrossRefGoogle Scholar
  99. Luo LY, Grass L, Howarth DJC, Pierre T, Ong H, Diamandis EP. (2001). Immunofluorometric assay of human kallikrein 10 and its identification in biological fluids and tissues, Clinical Chem 47, 237–46.Google Scholar
  100. Mayerhofer K, Bodner K, Bodner-Adler B, Schindl M, Kaider A, Hefler L, Zeillinger R, Leodolter S, Armin E, Kainz C. (2001). Interleukin-8 serum level shift in patients with ovarian carcinoma undergoing paclitaxel-containing chemotherapy, Cancer 91, 388–93.PubMedCrossRefGoogle Scholar
  101. McGuckin MA, Layton GT, Bailey MJ, Hurst T, Kho90 SK, Ward BG. (1990). Evaluation of two new assays for tumor-associated antigens, CASA and OSA, found in the serum of patients with epithelial ovarian carcinoma—comparison with CAl25, Gynecol Oncol 37, 165–71.PubMedCrossRefGoogle Scholar
  102. McKenzie SJ, DeSombre KA, Bast BS, Hollis DR, Whitaker RS, Berchuck A, Boyer CM, Bast RC Jr. (1993). Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer, Cancer 71, 3942–6.PubMedCrossRefGoogle Scholar
  103. Medl M, Ogris E, Peters-Engl C, Leodolter S. (1995). TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer, Br J Cancer 71, 1051–4.PubMedCrossRefGoogle Scholar
  104. Meisel M, Straube W, Weise J, Burkhardt B. (1995). A study of serum CASA and CA 125 levies in patients with ovarian cancer, Arch Gynecol Obstet 256, 9–15.PubMedCrossRefGoogle Scholar
  105. Menon U, Talaat A, Rosenthal AN, Macdonald ND, Jeyerajah AR, Skates SJ, Sibley K, Oram DH, Jacobs IJ. (2000). Performance of ultrasound as a second line test to serum CAl25 in ovarian cancer screening, Br J Obstet Gynecol 107, 165–69.CrossRefGoogle Scholar
  106. Mogensen O, Mogensen B, Jakobsen A. (1990). Tumor-associated trypsin inhibitor and cancer antigen 125 in pelvic masses, Gynecol Oncol 38, 170–4.PubMedCrossRefGoogle Scholar
  107. Mogensen O, Mogensen B, Jakobsen A. (1990). Tumour-associated tyrpsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours, Br J Cancer 61, 327–9.PubMedCrossRefGoogle Scholar
  108. Mogenson O, Mogensen B, Jakobsen A. (1989). Alpha 1-acid glucoprotein in ovarian cancer with a reference to immunosuppressive acidic protein and cancer antigen 125, Cancer 64, 1867–71.CrossRefGoogle Scholar
  109. Mok CH, Tsao SW, Knapp RC, Fishbaugh PM, Lau CC. (1992). Unifocal origin of advanced human epithelial ovarian cancer, Cancer Res 52, 5119–22.PubMedGoogle Scholar
  110. Mok SC, Chao J, Skates S, Wong K, Yiu GK, Muto MG, Berkowitz RS, Cramer DW. (2001). Prostasin, an upregulated gene in ovarian cancer, identified through microaaray technology. Tumor Markers: A New Era, Santa Barbara, CA.Google Scholar
  111. Muto MG, Welch WR, Mok SC, Bandera CA, Fishbauth PM, Tsao SW, Lau CC, Goodman HM, Knapp RC, Berkowitz. (1995). Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum., Cancer Res 55, 490–2.Google Scholar
  112. Nap M, Vitali A, Nustad K, Bast RC Jr, O’Brien TJ, Nilsson O, Seguin P, Suresh MR, Bormer OP, Saga T, de Bruijin HW, Nozawa S, Kreutz FT, Jette D, Sakahara H, Gadnell M, Endo K, Barlow EH, Warren D, Paus E, Hammarstrom S, Kenemans P, Hilgers J. (1996). Immunohistochemical characterization of 22 monoclonal antibodies against the CAl25 antigen: 2“d report from the ISOBM TD-1 Workshop, Tumour Biol 17, 325–31.PubMedCrossRefGoogle Scholar
  113. Negishi Y, Furukawa T, Oka T, Sakamoto M, Hirata T, Okabe K, Matayoshi K, Akiya K, Soma H. (1987). Clinical use of CA 125 and its combination assay with other tumor marker in patients with ovarian carcinoma, Gynecol Obstet Invest 23, 200–7.PubMedCrossRefGoogle Scholar
  114. Nishida Y, Kohno K, Kawamata T, Morimitsu K, Kuwano M, Miyakawa I. Increased cathepsin L levels in serum in some patients with ovarian cancer: comparison with CAl25 and CA724, Gynecol Oncol 56, 357–61.Google Scholar
  115. Nozawa S, Yajima M, Sakuma T, Udagawa Y, Kiguchi K, Sakayori M, Narisawa S, lizuka R, Uemura M. (1990). Cancer-associated galactosyltransferase as a new tumor marker for ovarian clear cell carcinoma, Cancer Res 50, 754–9.PubMedGoogle Scholar
  116. Oehler MK, Sutterlin M, Caffier H. (1999). CASA and CA 125 in diagnosis and follow-up of advanced ovarian cancer, Anticancer Res 19, 2513–8.PubMedGoogle Scholar
  117. Onsrud M, Shabana A, Austgulen R. (1996). Soluble tumor necrosis factor receptor and CA 125 in serum as markers for epithelial ovarian cancer, Tumour Biol 17, 90–6.PubMedCrossRefGoogle Scholar
  118. Panza N, Pacilio G, Campanella L, Peluso G, Battista C, Amoriello A, Utech W, Vacca G, Lombardi G. (1988). Cancer antigen 125, tissue polypeptide antigen, carcinoembryonic antigen, and beta-chain human chorionic gonadotropin as serum markers of epithelial ovarian carcinoma, Cancer 61, 76–83.PubMedCrossRefGoogle Scholar
  119. Pathuri B, Leitao M, Barakat RR, Akram M, Bogomolniy F, Olvera N, Lin O, Soslow R, Robson ME, Offit K, Boyd J. (2001). Genetic analysis of ovarian carcinoma histogenesis, Proc Soc Gyn Oncol 32: 43.Google Scholar
  120. Patsner B, Mann WJ, Visicchio M, Loesch M. (1988). Comparison of serum CAl25 and lipid-associated sialic acid ( LASA-P) in monitoring patients with invasive ovarian adenocarcinoma, Gynecol Oncol 30, 98–103.Google Scholar
  121. Pauler DK, Menon U, MCIntosh MW, Symecko HL, Skates SJ. (2001). Factors influencing serum CAl251I levels in healthy postmenopausal women, Cancer Epidemiol Biomarkers Prevention, in Dress.Google Scholar
  122. Peters-Engl C, Medl M, Ogris E, Leodolter S. (1995). Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CAl25) in patients with epithelial ovarian cancer, Anticancer Res 15, 2727–30.PubMedGoogle Scholar
  123. Petru E, Sevin BU, Averette HE, Koechli OR, Perras JP, Hilsenbeck S. (1990). Comparison of three tumor markers –CA-125, lipid-associated sialic acid (LSA), and NB/70K—in monitoring ovarian cancer, Gynecol Oncol 38, 181–6.PubMedCrossRefGoogle Scholar
  124. Phocas I, Sarandakou A, Sikiotis K, Rizos D, Kalambokis D, Zourlas PA. (1996). A comparative study of serum alpha-beta a immunoreactive inhibin and tumor-associated antigens CA 125 and CEA in ovarian cancer, Anticancer Res 16, 3827–31.PubMedGoogle Scholar
  125. Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, Gastl GA. (1994). Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer, Cancer 73, 1882–8.PubMedCrossRefGoogle Scholar
  126. Ries LAG, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK, (eds). (1999). SEER cancer statistics review 1973–1996, National Cancer Institute, Bethesda, MD.Google Scholar
  127. Robertson DM, Cahir N, Burger HG, Mamers P, McCloud PI, Pettersson K, McGuckin M. (1999). Combined inhibin and CAI25 assays in the detection of ovarian cancer, Clin Chem 45, 651–8.PubMedGoogle Scholar
  128. Rosenthal AN, Jacobs lJ. (1998), The role of CA 125 in screening for ovarian cancer, Int J Biol Makers 13, 216–20.Google Scholar
  129. Rosenthal A, Jacobs I, (1998). Ovarian Cancer Screening, Seminars Onc 25, 315–25.Google Scholar
  130. Rustin GJ, van der Burg ME, Berek JS. (1993). Advanced ovarian cancer. Tumour markers, Ann Oncol 4, 71–7.Google Scholar
  131. Santala M, Burger H, Ruokonen A, Stenback F, Kauppila A. (1998). Elevated serum inhibin and tumor-assocated trypsin inhibitor concentrations in a young woman with dysgerminoma of the ovary, Gynecol Oncol 71, 465–8.PubMedCrossRefGoogle Scholar
  132. Sato S, Yokoyama Y, Sakamota T, Futagami M, Saito Y. (2000). Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography, Cancer 89, 582–8.PubMedCrossRefGoogle Scholar
  133. Scambia G, Benedetti Panici P, Perrone L, Sonsini C, Giannelli S, Gallo A, Natali PG, Mancuso S. (1990). Serum levels of tumour assocated glycoprotein (TAG 72) in patients with gynaecological malignancies, Br J Cancer 62, 147–51.PubMedCrossRefGoogle Scholar
  134. Scambia G, Testa U, Panici PB, Martucci R, Foti E, Petrini M, Amoroso M, Masciullo V, Peschle C, Mancuso S. (1994). Interleukin-6 serum levels in patients with gynecological tumors, Int J Cancer 57, 318–23.PubMedCrossRefGoogle Scholar
  135. Scambia G, Testa U, Benedetti Panici P, Foti E, Martucci R, Gadducci A, Perillo A, Facchini V, Peschle C, Mancuso S. (1995). Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer, Br J Cancer 71, 354–6.PubMedCrossRefGoogle Scholar
  136. Schelling M, Braun M, Kuhn W. (2000). Combined transvaginal B-mode and color Doppler sonography for differential diagnosis of ovarian tumors: results of a multivariate logistic regression analysis, Gynecol Oncol 77, 78–86.PubMedCrossRefGoogle Scholar
  137. Schmandt RE, Clifford SL, Lee J, Lillie J, Deavers MT, Shaw P, Jung M, Levenback C, Bast RC, Mills GB, Gershenson DM, Lu KH. (2001). Differential expression of the secreted protease inhibitor, HE4, in epithelial ovarian cancer, Proc Soc Gynecol Oncol 32: 103.Google Scholar
  138. Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, Hellström KE, Hellström I. (1999). Soluble member(s) of the mesothelin/mega potentiating family are detectable in same from patients with ovarian carcinoma. Proc Natl Acad Sci USA 96, 11531–36.PubMedCrossRefGoogle Scholar
  139. Schummer M, Ng WL, Bumgarner RE, Nelson PS, Schummer B, Hassel L, Rae Baldwin L, Karlan BY, Hood L. (1999). Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas, Gene 238, 375–385.PubMedCrossRefGoogle Scholar
  140. Schutter EM, Mijatovic V, Kok A, Van Kamp GJ, Verstraeten R, Verheijen RH. (1999). Urinary gonadotropin peptide (UGP) and serum CA 125 in gynaecologic practice, a clinical prospective study, Anticancer Res 19, 5551–7.PubMedGoogle Scholar
  141. Schutter EM, Sohn C, Kristen P, Mobus V, Crombach G, Kaufmann M, Caffier H, Kreienberg R, Verstraeten AA, Kenemans P. (1998). Estimation of probability of malignancy using a logistic model combining physical examination, ultrasound, serum CA 125, aid serum CA 72–4 in postmenopusal women with a pelvic mass: an international multicenter study, Gynecol Oncol 69, 56–63.PubMedCrossRefGoogle Scholar
  142. Schwarz PE, Chambers JT, Taylor KJ, Pellerito J, flamers L, Cole LA, Yang-Feng TL, Smith P, Mayne ST, Makuch R. (1991). Early detection of ovarian cancer: preliminary results of the Yale Early Detection Program, Yale J Biol Med 64, 573–82.Google Scholar
  143. Schwartz PE, Chambers SK, Chambers JT, Gutmann J, Katopodis N, Foemmel R. (1987). Circulating tumor markers in the monitoring of gynecologic malignancies, Cancer 60, 35361.CrossRefGoogle Scholar
  144. Schvartsman HS, Lu KH, Le J, Lillie J, Deavers MT, Clifford SL, Wolf J, Mills GB, Bast RC, Gershenson DM, Schmandt RE. (2001). Over-expression of NES-1 in epithelial ovarian carcinoma, Society of Gynecologic 32“d Annual Meeting, Abstract, 103.Google Scholar
  145. Shridhar V, Lee J, Pandita A, Iturria S, Avula R, Staub J, Morrissey M, Calhoun E, Sen A, James D, Kalli K, Keeney G, Roche P, Cliby W, Mills GB, Bast RC Jr, Couch FJ, Hartmann LC, Lillie J, Smith DI. (2001). Genetic analysis of early versus late stage ovarian tumors, Cancer Res in press.Google Scholar
  146. Sichel F, Salaun V, Bar E, Gauduchon P, Malas JP, Goussard J, Le Talaer JY. (1994). Biological markers and ovarian carcinomas: galactosyltransferase, CA 125, isoenzymes of amylase and alkaline phosphatase, Clin Chim Acta, 227, 87–96.PubMedCrossRefGoogle Scholar
  147. Skates SJ, Jacobs IJ, MacDonald N, Rosenthal A, Menon U, Sibley K, Knapp RC. (1999). Estimated duration of pre-clinical ovarian cancer from longitudinal CAI 25 levels, Proc Amer Assoc Cancer Res 40: 43 (A#288).Google Scholar
  148. Skates SJ, Pauler DK. (2001). Screening based on the risk of cancer calculation from Bayesian Hierarchical change-point models of longitudinal markers, J Am Statist Assoc, in press.Google Scholar
  149. Skates SJ, Singer DE. (1991). Quantifying the potential benefit of CA 125 screening for ovarian cancer, J Clin Epidemiol 44, 365–80.PubMedCrossRefGoogle Scholar
  150. Skates SJ, Xu F-J, Yu Y-H, Sjövall K, Einhorn N, Chang YC, Bast RC Jr, and Knapp RC. (1995). Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers, Cancer 76, 2004–2010.PubMedCrossRefGoogle Scholar
  151. Sliutz G, Tempfer C, Kainz C, Mustafa G, Gitsch G, Koelbl H, Biegelmayer C. (1995). Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer, Anticancer Res 15, 1127–9.PubMedGoogle Scholar
  152. Stenman UH, Alfthan H, Vartiainen J, Lehtovirta P. (1995). Markers supplementing CA 125 in ovarian cancer, Ann Med 27, 115–20.PubMedCrossRefGoogle Scholar
  153. Stigbrand T, Riklund K, Tholander B, Hirano K, Lalos O, Stendahl U. (1990). Placental alkaline phosphatase (PLAP)/ PLAP-like alkaline phosphatase as tumour marker in relation to CA 125 and TPA for ovarian epithelial tumours, Eur J Gynaecol Oncol 11, 351–60.PubMedGoogle Scholar
  154. Szarka G, Pulay T, Csomor S, Tran-Phoung-Mai, Schumann B. (1988). The significance of neopterin determination as a tumour marker in ovarian cancer, Acta Chir Hung 29, 359–64.PubMedGoogle Scholar
  155. Tailor A, Jurkovic D, Bourne TH, Collins WP, Campbell S. (1997). Sonographic predication of malignancy in adnexal masses using multivariate logistic regression analysis, Ultrasound Obstet Gynecol 10, 41–7.PubMedCrossRefGoogle Scholar
  156. Tailor A, Jurkovic D, Bourne TH, Collins WP, Campbell S. (1999). Sonographic prediction of malignancy in adnexal masses using an artificial neural network, Br J Obstet Gynaecol 106, 21–30.PubMedCrossRefGoogle Scholar
  157. Tailor A, Jurkovic D, Bourne T, Natucci M, Collins WP, Campbell S. (1998). Comparison of transvaginal color Doppler imaging and color Doppler energy for assessment of intraovarian blood flow. Obstet Gynecol 91, 561–7.PubMedCrossRefGoogle Scholar
  158. Tekay A, Jouppila P. (1995). Blood flow in benign ovarian tumors and normal ovaries during the follicular phase. Obstet Gynecol 86, 55–9.PubMedCrossRefGoogle Scholar
  159. Tempfer C, Hefler L, Heinz! H, Loesch A, Gitsch G, Rumpold H, Kainz C. CYFRA 21–1 serum levels in women with adnexal masses and inflammatory diseases, Br J Cancer 78, 1108–12.Google Scholar
  160. Tholander B, Taube A, Lindgren A, Sjoberg O, Stendahl U, Tamsen L. (1990). Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phophatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease, Gynecol Oncol 39, 36–33.Google Scholar
  161. Tholander B, Taube A, Lindgren A, Sjoberg O, Stendahl U, Kiviranta A, Hallman K, Holm L, Weiner E, Tamsen L. (1990). Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phophatase, in patients with ovarian carcinoma, borderline tumors, or benign adnexal masses: relevance for differential diagnosis, Gynecol Oncol 39, 16–25.PubMedCrossRefGoogle Scholar
  162. Timmerman D, Verreist H, Boume TH, De Moor B, Collins WP, Vergote I, Vandewalle J. (1999). Artificial neural network models for the preoperative discrimination between malignant and benign adnexal masses, Ultrasound Obstet Gynecol, 13, 17–25.PubMedCrossRefGoogle Scholar
  163. Toftager-Larsen K, Hording U, Dreisler A, Daugaard S, Lund B, Bock J, Lundvall F, Frederiksen K, Norgaard-Pedersen B. (1992). CA-125, placental alkaline phosphatas and tissue polypeptide antigen as preoperative serum markers in ovarian carcinoma, Gynecol Obstet Invest 33, 177–82.PubMedCrossRefGoogle Scholar
  164. Tuxen MK, Soletormos G, Petersen PH, Schioler V, Dombernowski P. (1999). Assessment of biological variation and analytical imprecision of CA 125, CEA, and TPA in relation to monitoring of ovarian cancer, Gynecol Oncol 74, 12–22.Google Scholar
  165. Urban N, Drescher C, Etzioni R, Colby C. (1997). Use of a stochastic simulation model to identify and efficient protocol for ovarian cancer screening, Controlled Clin Trials 18, 25170.CrossRefGoogle Scholar
  166. Urban N. Screening for ovarian cancer. Br Med J 1999; 319: 1317–8CrossRefGoogle Scholar
  167. Valentin L, Sladkevicius P, Marsal K. (1994). Limited contribution of Doppler velocimetry to the differential diagnosis of extrauterine pelvic tumors. Obstet Gynecol 83, 425–33.PubMedGoogle Scholar
  168. Van Haaften-Day C, Xu F, Yu Y, Bast, RC Jr, Hacker N. (2001). OVXI, CA 125 and M-CSF as tumor markers for surface epithelial-stromal tumors of the ovary - a critical appraisal, Cancer In Revision.Google Scholar
  169. Van Nagell JR, Depriest PD, Reedy MB, Gallion HH, Ueland FR, Pavlik EJ, Kryscio RI. (2000). The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer, Gynecol Oncol 77, 350–56.PubMedCrossRefGoogle Scholar
  170. Vardi JR, Tadros GH, Foemmel R, Shebes M. (1989). Plasma Lipid-associated sialic acid and serum CA 125 as indicators of disease status with advanced ovarian cancer, Obstet Gynecol 74, 379–83.PubMedGoogle Scholar
  171. Walker R, Crebbin V, Stem J, Scudder S, Schwartz P. (1994). Urinary gonadotropin peptide ( UGP) as a marker of gynecologic malignancies, Anticancer Res 14, 1703–9.Google Scholar
  172. Wang K, Gan L, Jeffery E, Gayle M, Gown AM, Skelly M, Nelson PS, Ng WP, Schummer M, Hood L, Mulligan J. (1999). Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray, Gene 229: 101–8.PubMedCrossRefGoogle Scholar
  173. Wang YX, Schwartz PE, Chambers JT, Cole LA. (1988). Urinary gonadotropin fragments (UGF) in cancers of the female reproductive system. II. Initial serial studies, Gyncol Oncol 31, 91–102.Google Scholar
  174. Ward BG, Cruickshank DJ, Tucker DF, Love S. (1987). Independent expression in serum of three tumour-associated antigens: CA 125, placental alkaline phosphatase and HMFG2 in ovarian carcinoma, Br J Obstet Gynaecol 94, 696–8.PubMedCrossRefGoogle Scholar
  175. Ward BG, McGuckin MA, Ramm LE, Goglan M, Sanderson B, Tripcony L, Free KE. (1993). The management of ovarian carcinoma is improved by the use of cancer-associated serum antigen and CA 125 assays, Cancer 71, 430–8.PubMedCrossRefGoogle Scholar
  176. Westhoff C, Gollub E, Patel J, Rivera H, Bast R Jr. (1990). CA 125 levels in menopausal women, Obstet Gynecol 76, 428–431.PubMedGoogle Scholar
  177. Woolas RP, Conaway MR, Fengji X, Jacobs IJ, Yu Y, Daly L, Davies AP, O’Briant K, Berchuck A, Soper JT, Clarke-Pearson DL, Rodriquez G, Oram DH, Bast RC. (1995). Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses, Gynecol Oncol 59, 111–16.PubMedCrossRefGoogle Scholar
  178. Woolas RP, Oram DH, Jeyarajah AR, Bast RC, Jacobs U. (1999). Ovarian cancer identified through screening with serum markers but not by pelvic imaging, Int J Gynecol Cancer 9, 497–501.PubMedCrossRefGoogle Scholar
  179. Woolas RP, Xu FJ, Jacobs II, Yu Y, Daly L, Berchuck A, Soper JT, Clark-Pearson DL, Oram DH, Bast RC. (1993) Elevation of multiple serum markers in patients with stage I ovarian cancer. J Nati Cancer Inst 85, 1748–51.CrossRefGoogle Scholar
  180. Xu FJ, Ramakrishnan S, Daly L, Soper JT, Berchuck A, Clarke-Pearson D, Bast RC Jr. (1991). Increased serum levels of macrophage colony-stimulating factor in ovarian cancer, Am J Obstet Gynecol 165, 1356–1362.PubMedGoogle Scholar
  181. Xu F-J, Yu Y-A, Daly L, DeSombre K, Anselmino L, Hass GM, Berchuck A, Soper J, Clarke-Pearson D, Boyer C, Layfield LJ, Bast RC Jr. (1993). OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures, J Clin Oncol 11, 1506–1510.PubMedGoogle Scholar
  182. Xu FJ, Yu YH, Li BY, Moradi M, Elg S, Lane C, Carson L, Ramakrishnan S. (1991). Development of two new monoclonal antibodies reactive to a surface antigen present on human ovarian epithelial cancer cells, Cancer Res 51; 4012–9.PubMedGoogle Scholar
  183. Xu Y, Gaudette DC, Boynton JD, Frankel A, Fang XL, Sharma A, Hurteau J, Casey G, Goodbody A, Mellors A. (1995). Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients, Clin Cancer Res 1, 1223–32.Google Scholar
  184. Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, Kennedy AW, Belinson J, Markman M, Casey G. (1998). Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers, JAMA 280; 719–23.PubMedCrossRefGoogle Scholar
  185. Zakrzewska I, Borawska R, Poznanski J, Mackowiak B. (1999). Significance of some tumor markers in differential diagnosis of ovarian cancer, Rocz Akad Med Bialymst 44, 235–43.PubMedGoogle Scholar
  186. Zhang Z, Bamhill SD, Zhang H, Xu F, Yu Y, Jacobs I, Woolas RP, Berchuck A, Madyastha KR, Bast RC. (1999). Combination of multiple serum markers using an artificial neural network to improve specificity on discriminating malignant from benign pelvic masses, Gynecol Oncol 73, 56–61.PubMedCrossRefGoogle Scholar
  187. Zhang Z, Xu F, Yu Y, Berchuck A, Havrilesky LJ, de Bruijn HWA, vader Zee AGJ, Woolas RP, Jacobs I, Bast RC. (2001). Use of multiple markers to detect stage I epithelial ovarian cancers: neural network analysis improves performance. Proc Amer Soc Clin Oncol, in press.Google Scholar
  188. Zurawski VR Jr, Orjaseter H, Anderson A, Jellum E. (1988). Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia; relevance for early detection of ovarian cancer, Int J Cancer 42, 677–80.PubMedCrossRefGoogle Scholar
  189. Zurawski VR, Knapp RC, Einhorn N, Kenemans P, Mortel R, Ohmi K, Bast RC, Ritts RE, Malkasian G. (1988). An initial analysis of pre operative serum CA 125 levels in patients with early stage ovarian carcinoma, Gynecol Oncol 30, 7–14.Google Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Robert C. BastJr.
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
  • Nicole Urban
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
  • Viji Shridhar
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
  • David Smith
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
  • Zhen Zhang
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
  • Steven Skates
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
  • Karen Lu
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
  • Jinsong Liu
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
  • David Fishman
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
  • Gordon Mills
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
  1. 1.Departments of Experimental Therapeutics, Molecular Therapeutics, Gynecologic Oncology, Anatomic PathologyUniversity of Texas M.D. Anderson Cancer CenterHoustonUSA
  2. 2.Departments of Experimental Therapeutics, Molecular Therapeutics, Gynecologic Oncology, Anatomic PathologyThe Fred Hutchinson Cancer CenterSeattleUSA
  3. 3.Departments of Experimental Therapeutics, Molecular Therapeutics, Gynecologic Oncology, Anatomic PathologyMayo ClinicRochesterUSA
  4. 4.Departments of Experimental Therapeutics, Molecular Therapeutics, Gynecologic Oncology, Anatomic PathologyMedical University of South CarolinaCharlestonUSA
  5. 5.Departments of Experimental Therapeutics, Molecular Therapeutics, Gynecologic Oncology, Anatomic PathologyMassachusetts General HospitalBostonUSA
  6. 6.Departments of Experimental Therapeutics, Molecular Therapeutics, Gynecologic Oncology, Anatomic PathologyNorthwestern University Medical SchoolChicagoUSA

Personalised recommendations